154 related articles for article (PubMed ID: 38791096)
1. Alterations in Peripheral Lymphocyte Subsets under Immunochemotherapy in Stage IV SCLC Patients: Th17 Cells as Potential Early Predictive Biomarker for Response.
Schmälter AK; Löhr P; Konrad M; Waidhauser J; Arndt TT; Schiele S; Thoma A; Hackanson B; Rank A
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791096
[TBL] [Abstract][Full Text] [Related]
2. Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study.
Xie M; Vuko M; Rodriguez-Canales J; Zimmermann J; Schick M; O'Brien C; Paz-Ares L; Goldman JW; Garassino MC; Gay CM; Heymach JV; Jiang H; Barrett JC; Stewart RA; Lai Z; Byers LA; Rudin CM; Shrestha Y
Mol Cancer; 2024 May; 23(1):115. PubMed ID: 38811992
[TBL] [Abstract][Full Text] [Related]
3. The prognostic role of circulating CD8
An N; Wang H; Jia W; Jing W; Liu C; Zhu H; Yu J
J Transl Med; 2019 Dec; 17(1):402. PubMed ID: 31796037
[TBL] [Abstract][Full Text] [Related]
4. High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers.
Chang YL; Yang CY; Huang YL; Wu CT; Yang PC
Oncotarget; 2017 Mar; 8(11):18021-18030. PubMed ID: 28152514
[TBL] [Abstract][Full Text] [Related]
5. FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III.
Jiang M; Wu C; Zhang L; Sun C; Wang H; Xu Y; Sun H; Zhu J; Zhao W; Fang Q; Yu J; Chen P; Wu S; Zheng Z; He Y; Zhou C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006632
[TBL] [Abstract][Full Text] [Related]
6. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
Yan Y; Wang X; Liu C; Jia J
BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
[TBL] [Abstract][Full Text] [Related]
7. Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.
Ragavan M; Das M
Curr Treat Options Oncol; 2020 Jun; 21(8):64. PubMed ID: 32601742
[TBL] [Abstract][Full Text] [Related]
8. Pegylated recombinant human granulocyte colony-stimulating factor regulates the immune status of patients with small cell lung cancer.
Sun J; Bai H; Wang Z; Duan J; Li J; Guo R; Wang J
Thorac Cancer; 2020 Mar; 11(3):713-722. PubMed ID: 32020764
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
Zhang S; Li S; Cheng Y
Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
[TBL] [Abstract][Full Text] [Related]
10. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
11. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
Konala VM; Madhira BR; Ashraf S; Graziano S
Oncology; 2020; 98(11):749-754. PubMed ID: 32663833
[TBL] [Abstract][Full Text] [Related]
12. CD8+CD28- cells and CD4+CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients.
Karagöz B; Bilgi O; Gümüs M; Erikçi AA; Sayan O; Türken O; Kandemir EG; Oztürk A; Yaylaci M
Med Oncol; 2010 Mar; 27(1):29-33. PubMed ID: 19148592
[TBL] [Abstract][Full Text] [Related]
13. Analyzing the percentage of different PD-1
Hu X; Gu Y; Li D; Zhao S; Hua S; Jiang Y
Clin Exp Pharmacol Physiol; 2019 Dec; 46(12):1074-1083. PubMed ID: 31381177
[TBL] [Abstract][Full Text] [Related]
14. Peripheral CD4
Yang X; Li Q; Zeng T
Front Immunol; 2024; 15():1364507. PubMed ID: 38650951
[TBL] [Abstract][Full Text] [Related]
15. Aberrant Alteration of Circulating Lymphocyte Subsets in Small Cell Lung Cancer Patients Treated with Radiotherapy.
Li H; Yu H; Lan S; Zhao D; Liu Y; Cheng Y
Technol Cancer Res Treat; 2021; 20():15330338211039948. PubMed ID: 34851203
[No Abstract] [Full Text] [Related]
16. Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort.
Schmid S; Mauti LA; Friedlaender A; Blum V; Rothschild SI; Bouchaab H; Frösch P; Britschgi C; König D; Wannesson L; Janthur WD; Schär S; Demmer I; Addeo A; Jochum W; Früh M
Cancer Immunol Immunother; 2020 Aug; 69(8):1605-1613. PubMed ID: 32307579
[TBL] [Abstract][Full Text] [Related]
17. Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage.
Koyama K; Kagamu H; Miura S; Hiura T; Miyabayashi T; Itoh R; Kuriyama H; Tanaka H; Tanaka J; Yoshizawa H; Nakata K; Gejyo F
Clin Cancer Res; 2008 Nov; 14(21):6770-9. PubMed ID: 18980970
[TBL] [Abstract][Full Text] [Related]
18. Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors.
Reddy HG; Qin A; Kalemkerian GP
Expert Opin Emerg Drugs; 2020 Sep; 25(3):353-366. PubMed ID: 32683991
[TBL] [Abstract][Full Text] [Related]
19. Neuron - specific enolase predicts the prognosis in advanced small cell lung cancer patients treated with first-line PD-1/PD-L1 inhibitors.
Li L; Zhang Z; Hu Y
Medicine (Baltimore); 2021 Sep; 100(36):e27029. PubMed ID: 34516493
[TBL] [Abstract][Full Text] [Related]
20. [Distribution and Clinical Significance of CTLA-4, PD-1 and PD-L1 in Peripheral Blood of Patients with Small Cell Lung Cancer].
Li H; Liu Y; Liu Y; Liu J; Zhao D; Wang Y; Cheng Y
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):755-760. PubMed ID: 29167005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
